Equity
Total Liabilities & Equity
Bristol-Myers Squibb Total Liabilities & Equity decreased by 4.0% to $86.48B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.4%, from $92.43B to $86.48B. Over 5 years (FY 2020 to FY 2025), Total Liabilities & Equity shows a downward trend with a -5.3% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryOther
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ1 2026Apr 30, 2026
How to read this metric
Growth in this figure indicates an expansion of the company's asset base, typically through debt or equity financing.
Detailed definition
This metric represents the sum of all liabilities and total stockholders' equity, which must equal the total assets of t...
Peer comparison
Used as a baseline for comparing the size and capital intensity of pharmaceutical companies.
Metric ID:
total_liabilities_and_equityHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $110.80B | $110.89B | $109.31B | $103.03B | $100.36B | $98.20B | $96.82B | $94.28B | $93.49B | $91.26B | $95.16B | $99.03B | $94.65B | $93.67B | $92.60B | $92.43B | $94.68B | $96.89B | $90.04B | $86.48B |
| QoQ Change | — | +0.1% | -1.4% | -5.7% | -2.6% | -2.2% | -1.4% | -2.6% | -0.8% | -2.4% | +4.3% | +4.1% | -4.4% | -1.0% | -1.1% | -0.2% | +2.4% | +2.3% | -7.1% | -4.0% |
| YoY Change | — | — | — | — | -9.4% | -11.4% | -11.4% | -8.5% | -6.8% | -7.1% | -1.7% | +5.0% | +1.2% | +2.6% | -2.7% | -6.7% | +0.0% | +3.4% | -2.8% | -6.4% |
Range$86.48B – $110.89B
CAGR-5.1%
Avg YoY Growth-3.9%
Median YoY Growth-4.6%
Current Streak2 quarters decline
Total Liabilities & Equity at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's total liabilities & equity?
- Bristol-Myers Squibb (BMY) reported total liabilities & equity of $86.48B in Q1 2026.
- How has Bristol-Myers Squibb's total liabilities & equity changed year-over-year?
- Bristol-Myers Squibb's total liabilities & equity decreased by 6.4% year-over-year, from $92.43B to $86.48B.
- What is the long-term trend for Bristol-Myers Squibb's total liabilities & equity?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's total liabilities & equity has grown at a -5.3% compound annual growth rate (CAGR), from $118.48B to $90.04B.
- What does total liabilities & equity mean?
- The total balance sheet size, representing the sum of all funding sources.